Literature DB >> 21769488

Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation.

J Rech1, B Manger, B Lang, G Schett, M Wilhelm, J Birkmann.   

Abstract

Still's disease and chronic recurrent multifocal osteomyelitis (CRMO) are febrile rheumatic diseases of unknown etiology, which predominantly affect children but can also have their initial manifestation in adults. Both can present as intermittent, relapsing episodes and are considered potential candidates within the expanding spectrum of autoinflammatory disorders, although no genetic abnormalities have been described for either of them. Here, we describe a man with an initial manifestation of abacterial multifocal osteitis at the age of 41. During a relapsing-remitting course of his illness, he increasingly developed symptoms of adult-onset Still's disease (AOSD), and the diagnosis was established according to the Yamaguchi criteria. When treated with anakinra, not only the acute symptoms disappeared promptly, but also the osteitis went into complete remission. This is to our knowledge the first description of a simultaneous occurrence of these two manifestations of autoinflammation in adulthood.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769488     DOI: 10.1007/s00296-011-2020-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  6 in total

1.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.

Authors:  Ivona Aksentijevich; Seth L Masters; Polly J Ferguson; Paul Dancey; Joost Frenkel; Annet van Royen-Kerkhoff; Ron Laxer; Ulf Tedgård; Edward W Cowen; Tuyet-Hang Pham; Matthew Booty; Jacob D Estes; Netanya G Sandler; Nicole Plass; Deborah L Stone; Maria L Turner; Suvimol Hill; John A Butman; Rayfel Schneider; Paul Babyn; Hatem I El-Shanti; Elena Pope; Karyl Barron; Xinyu Bing; Arian Laurence; Chyi-Chia R Lee; Dawn Chapelle; Gillian I Clarke; Kamal Ohson; Marc Nicholson; Massimo Gadina; Barbara Yang; Benjamin D Korman; Peter K Gregersen; P Martin van Hagen; A Elisabeth Hak; Marjan Huizing; Proton Rahman; Daniel C Douek; Elaine F Remmers; Daniel L Kastner; Raphaela Goldbach-Mansky
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 2.  Adult-onset Still disease.

Authors:  Bruno Fautrel
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-10       Impact factor: 4.098

3.  Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood.

Authors:  Despina Eleftheriou; Tommy Gerschman; Neil Sebire; Patricia Woo; Clarissa A Pilkington; Paul A Brogan
Journal:  Rheumatology (Oxford)       Date:  2010-04-29       Impact factor: 7.580

4.  [Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra].

Authors:  A K Klein; G Horneff
Journal:  Klin Padiatr       Date:  2010-02-04       Impact factor: 1.349

Review 5.  Autoinflammatory bone disorders.

Authors:  Polly J Ferguson; Hatem I El-Shanti
Journal:  Curr Opin Rheumatol       Date:  2007-09       Impact factor: 5.006

Review 6.  Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment.

Authors:  Heleen D de Koning; Evelien J Bodar; Jos W M van der Meer; Anna Simon
Journal:  Semin Arthritis Rheum       Date:  2007-06-21       Impact factor: 5.532

  6 in total
  16 in total

1.  Chronic recurrent multifocal osteomyelitis with an atypical presentation in an adult man.

Authors:  Cheng William Hong; Edward C Hsiao; Andrew E Horvai; Thomas M Link
Journal:  Skeletal Radiol       Date:  2015-03-17       Impact factor: 2.199

2.  Palmoplantar pustules and osteoarticular pain in a 42-year-old woman.

Authors:  Rena C Zuo; Daniella M Schwartz; Chyi-Chia Richard Lee; Milan J Anadkat; Edward W Cowen; Haley B Naik
Journal:  J Am Acad Dermatol       Date:  2014-08-12       Impact factor: 11.527

3.  Successful treatment of chronic recurrent multifocal osteomyelitis using low-dose radiotherapy : A case report.

Authors:  Christian T Dietzel; Christoph Schäfer; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2016-11-07       Impact factor: 3.621

4.  Inflammasome-independent IL-1β mediates autoinflammatory disease in Pstpip2-deficient mice.

Authors:  Suzanne L Cassel; John R Janczy; Xinyu Bing; Shruti P Wilson; Alicia K Olivier; Jesse E Otero; Yoichiro Iwakura; Dmitry M Shayakhmetov; Alexander G Bassuk; Yousef Abu-Amer; Kim A Brogden; Trudy L Burns; Fayyaz S Sutterwala; Polly J Ferguson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

Review 5.  The SAPHO syndrome revisited with an emphasis on spinal manifestations.

Authors:  Antonio Leone; Victor N Cassar-Pullicino; Roberto Casale; Nicola Magarelli; Alessia Semprini; Cesare Colosimo
Journal:  Skeletal Radiol       Date:  2014-10-21       Impact factor: 2.199

Review 6.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 7.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

8.  Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still's disease.

Authors:  F Nonaka; K Migita; Y Jiuchi; T Shimizu; M Umeda; N Iwamoto; K Fujikawa; Y Izumi; A Mizokami; M Nakashima; Y Ueki; M Yasunami; A Kawakami; K Eguchi
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

9.  Efficacy of anti-IL-1 treatment in Majeed syndrome.

Authors:  Troels Herlin; Bente Fiirgaard; Mette Bjerre; Gitte Kerndrup; Henrik Hasle; Xinyu Bing; Polly J Ferguson
Journal:  Ann Rheum Dis       Date:  2012-10-20       Impact factor: 19.103

Review 10.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.